A Phase 3 Trial of Telitacicept for Systemic Lupus Erythematosus

Ronald F. van Vollenhoven

Department of Rheumatology, Amsterdam University Medical Center and Amsterdam Rheumatology Center, Amsterdam

Li Wang

The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital Zhengzhou China

Joan T. Merrill

Oklahoma Medical Research Foundation, University of Oklahoma Health Sciences Center, Oklahoma City

Yi Liu

Chunde Bao

Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai

Fen Li

Second Xiangya Hospital of Central South University, Changsha, China

Jiankang Hu

Pingxiang People’s Hospital, Pingxiang, China

Chenghui Huang

Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, China

Jianhong Zhao

Jining No.1 People’s Hospital, Jining, China

Cibo Huang

Beijing Hospital, Beijing

Hanyou Mo

Affiliated Hospital of Guilin Medical University, Guilin, China

Wei Wei

Fu’ai Lu

First Affiliated Hospital of Baotou Medical College of Inner Mongolia University of Science and Technology, Baotou, China

Jingyang Li

Zhuzhou Central Hospital, Zhuzhou, China

Dongbao Zhao

Shanghai Changhai Hospital, Shanghai

Wenxiang Wang

RemeGen, Yantai, China

Lin Li

Qing Zuraw

Vor Biopharma, Boston

Xiaofei Wang

College of Chemistry and Molecular Sciences, Wuhan University, Wuhan 430072, China

Xuebin Wang

Jianmin Fang

RemeGen, Yantai, China

Fengchun Zhang

Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, National Clinical Research Center for Dermatologic and Immunologic Diseases, State Key Laboratory of Complex Severe and Rare Diseases, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing